Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $29.00 USD
Change Today -0.22 / -0.75%
Volume 2.0M
HZNP On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

horizon pharma plc (HZNP) Snapshot

Open
$28.32
Previous Close
$29.22
Day High
$29.49
Day Low
$28.00
52 Week High
07/20/15 - $39.49
52 Week Low
09/5/14 - $9.46
Market Cap
4.6B
Average Volume 10 Days
2.6M
EPS TTM
$-0.26
Shares Outstanding
159.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HORIZON PHARMA PLC (HZNP)

horizon pharma plc (HZNP) Related Businessweek News

No Related Businessweek News Found

horizon pharma plc (HZNP) Details

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; PENNSAID for the treatment of pain of OA of the knee; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA, and ankylosing spondylitis (AS). It also provides RAYOS/LODOTRA, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active RA in adults when accompanied by morning stiffness, as well as for the treatment of polymyalgia rheumatica, psoriatic arthritis, AS, asthma, chronic obstructive pulmonary disease, and various other conditions. The company has a collaboration agreement with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer. Horizon Pharma plc was founded in 2005 and is headquartered in Dublin, Ireland.

692 Employees
Last Reported Date: 08/7/15
Founded in 2005

horizon pharma plc (HZNP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $982.3K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $210.9K
Chief Business Officer and Executive Vice Pre...
Total Annual Compensation: $492.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $396.3K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $194.5K
Compensation as of Fiscal Year 2014.

horizon pharma plc (HZNP) Key Developments

Horizon Pharma plc Names George Hampton as Executive Vice President, Global Orphan Business Unit and International Operations

Horizon Pharma plc named George Hampton as executive vice president, global orphan business unit and international operations, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Hampton has also joined the Horizon's Executive Committee. Hampton joined Horizon Pharma in 2008 as a consultant and full time as a group vice president, international operations in April 2015. Most recently, Hampton served as president and chief executive officer of a privately held technology company.

Horizon Pharma plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year 2015

Horizon Pharma plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues were $172,821,000 compared to $66,062,000 a year ago. Operating loss was $33,173,000 compared to $7,100,000 a year ago. Loss before expense for income taxes was $128,866,000 compared to $26,889,000 a year ago. Net income was $31,814,000 or $0.20 diluted per share compared to net loss of $27,769,000 or $0.38 per basic and diluted per share a year ago. Net cash provided by operating activities was $41,584,000 compared to $16,761,000 a year ago. Purchase of property and equipment was $704,000 compared to $543,000 a year ago. Adjusted Non-GAAP net income was $61,898,000 compared to $19,766,000 a year ago. Diluted adjusted Non-GAAP earnings per share was $0.39 against $0.20 a year ago. Non-GAAP cash provided by operating activities was $129,595,000 compared to $20,130,000 a year ago. Adjusted operating cash flow in the second quarter of 2015 as $129.6 million. LBITDA was $69,821,000 compared to $14,457,000 a year ago. Adjusted EBITDA was $76,050,000 compared to $21,479,000 a year ago. For the six months, revenues were $285,962,000 compared to $117,988,000 a year ago. Operating loss was $28,409,000 compared to $5,513,000 a year ago. Loss before expense for income taxes was $146,506,000 compared to $234,244,000 a year ago. Net income was $12,261,000 or $0.08 diluted per share compared to $234,019,000 or $3.34 diluted per share a year ago. Net cash used in operating activities was $29,155,000 compared to net cash provided by operating activities of $16,004,000 a year ago. Purchase of property and equipment was $2,281,000 compared to $1,037,000 a year ago. Adjusted Non-GAAP net income was $86,405,000 compared to $26,804,000 a year ago. Diluted adjusted Non-GAAP earnings per share was $0.60 against $0.29 a year ago. LBITDA was $53,033,000 compared to $212,363,000 a year ago. Adjusted EBITDA was $86,405,000 compared to $26,804,000 a year ago. Non-GAAP cash provided by operating activities was $161,547,000 compared to $242,593,000 a year ago. For the full year 2015, the company expects net sales to be in the range of $660 to $680 million and Adjusted EBITDA to be in the range of $265 to $280 million.

Horizon Pharma Seeks Acquisitions

Horizon Pharma plc (NasdaqGS:HZNP) is seeking acquisitions. Paul Hoelscher, Chief Financial Officer, said, "We continue to be aggressive in our pursuit of M&A opportunities. To that end, as we've previously stated future acquisitions may impact these forecasted rates and we will update our guidance as appropriate when that happens."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZNP:US $29.00 USD -0.22

HZNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $73.48 USD -3.52
Pfizer Inc $31.36 USD -0.86
View Industry Companies
 

Industry Analysis

HZNP

Industry Average

Valuation HZNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.5x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON PHARMA PLC, please visit www.horizonpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.